Venus Concept (VERO) Competitors $0.31 0.00 (0.00%) As of 05/21/2026 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock VERO vs. GCTK, LYRA, SSKN, DYNT, and XAGEShould you buy Venus Concept stock or one of its competitors? MarketBeat compares Venus Concept with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venus Concept include GlucoTrack (GCTK), Lyra Therapeutics (LYRA), Strata Skin Sciences (SSKN), Dynatronics (DYNT), and Longevity Health (XAGE). These companies are all part of the "medical equipment" industry. VERO vs. GCTKVERO vs. LYRAVERO vs. SSKNVERO vs. DYNTVERO vs. XAGEHow does Venus Concept compare to GlucoTrack?Venus Concept (NASDAQ:VERO) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Does the media prefer VERO or GCTK? In the previous week, Venus Concept's average media sentiment score of 0.00 equaled GlucoTrack'saverage media sentiment score. Company Overall Sentiment Venus Concept Neutral GlucoTrack Neutral Which has more risk & volatility, VERO or GCTK? Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Do analysts recommend VERO or GCTK? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable earnings & valuation, VERO or GCTK? GlucoTrack has lower revenue, but higher earnings than Venus Concept. GlucoTrack is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVenus Concept$58.88M0.01-$47M-$48.84N/AGlucoTrackN/AN/A-$19.39M-$18.04N/A Do insiders & institutionals believe in VERO or GCTK? 87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by insiders. Comparatively, 2.2% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is VERO or GCTK more profitable? GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. GlucoTrack's return on equity of -581.98% beat Venus Concept's return on equity.Company Net Margins Return on Equity Return on Assets Venus Concept-92.76% -1,904.25% -85.22% GlucoTrack N/A -581.98%-220.10% SummaryVenus Concept and GlucoTrack tied by winning 5 of the 10 factors compared between the two stocks.How does Venus Concept compare to Lyra Therapeutics?Lyra Therapeutics (NASDAQ:LYRA) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Do analysts recommend LYRA or VERO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility & risk, LYRA or VERO? Lyra Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Is LYRA or VERO more profitable? Venus Concept has a net margin of -92.76% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Venus Concept's return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-5,491.17% -1,010.91% -58.92% Venus Concept -92.76%-1,904.25%-85.22% Which has stronger valuation & earnings, LYRA or VERO? Venus Concept has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$600K2.22-$93.43M-$19.15N/AVenus Concept$58.88M0.01-$47M-$48.84N/A Does the media prefer LYRA or VERO? In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score. Company Overall Sentiment Lyra Therapeutics Neutral Venus Concept Neutral Do institutionals and insiders believe in LYRA or VERO? 95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryLyra Therapeutics beats Venus Concept on 7 of the 12 factors compared between the two stocks.How does Venus Concept compare to Strata Skin Sciences?Venus Concept (NASDAQ:VERO) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Does the media refer more to VERO or SSKN? In the previous week, Strata Skin Sciences had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Strata Skin Sciences and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Strata Skin Sciences'average media sentiment score. Company Overall Sentiment Venus Concept Neutral Strata Skin Sciences Neutral Which has more risk & volatility, VERO or SSKN? Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Strata Skin Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Do analysts recommend VERO or SSKN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals and insiders hold more shares of VERO or SSKN? 87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 32.4% of Strata Skin Sciences shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 40.9% of Strata Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, VERO or SSKN? Strata Skin Sciences has lower revenue, but higher earnings than Venus Concept. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVenus Concept$58.88M0.01-$47M-$48.84N/AStrata Skin Sciences$30.98M0.03-$10.09M-$1.41N/A Is VERO or SSKN more profitable? Strata Skin Sciences has a net margin of -35.64% compared to Venus Concept's net margin of -92.76%. Strata Skin Sciences' return on equity of -476.73% beat Venus Concept's return on equity.Company Net Margins Return on Equity Return on Assets Venus Concept-92.76% -1,904.25% -85.22% Strata Skin Sciences -35.64%-476.73%-33.49% SummaryStrata Skin Sciences beats Venus Concept on 9 of the 12 factors compared between the two stocks.How does Venus Concept compare to Dynatronics?Venus Concept (NASDAQ:VERO) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings. Do institutionals & insiders believe in VERO or DYNT? 87.4% of Venus Concept shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 2.9% of Dynatronics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is VERO or DYNT more profitable? Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.Company Net Margins Return on Equity Return on Assets Venus Concept-92.76% -1,904.25% -85.22% Dynatronics -8.35%-41.81%-9.56% Which has more volatility & risk, VERO or DYNT? Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Does the media refer more to VERO or DYNT? In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score. Company Overall Sentiment Venus Concept Neutral Dynatronics Neutral Do analysts rate VERO or DYNT? Given Dynatronics' higher probable upside, analysts clearly believe Dynatronics is more favorable than Venus Concept.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, VERO or DYNT? Dynatronics has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVenus Concept$58.88M0.01-$47M-$48.84N/ADynatronics$33.60M0.00-$2.70M-$1.35N/A SummaryDynatronics beats Venus Concept on 7 of the 12 factors compared between the two stocks.How does Venus Concept compare to Longevity Health?Longevity Health (NASDAQ:XAGE) and Venus Concept (NASDAQ:VERO) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership. Do analysts prefer XAGE or VERO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable valuation & earnings, XAGE or VERO? Longevity Health has higher earnings, but lower revenue than Venus Concept. Longevity Health is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongevity Health$1.05M0.54-$10.37M-$4.29N/AVenus Concept$58.88M0.01-$47M-$48.84N/A Does the media favor XAGE or VERO? In the previous week, Longevity Health's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score. Company Overall Sentiment Longevity Health Neutral Venus Concept Neutral Is XAGE or VERO more profitable? Venus Concept has a net margin of -92.76% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Venus Concept's return on equity.Company Net Margins Return on Equity Return on Assets Longevity Health-682.67% N/A -261.90% Venus Concept -92.76%-1,904.25%-85.22% Which has more volatility & risk, XAGE or VERO? Longevity Health has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Do insiders and institutionals hold more shares of XAGE or VERO? 24.2% of Longevity Health shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryLongevity Health and Venus Concept tied by winning 6 of the 12 factors compared between the two stocks. Get Venus Concept News Delivered to You Automatically Sign up to receive the latest news and ratings for VERO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERO vs. The Competition ExportMetricVenus ConceptMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$442K$6.97B$6.38B$12.34BDividend YieldN/A1.67%2.79%5.33%P/E Ratio-0.0149.7220.9125.65Price / Sales0.0184.92543.8085.61Price / CashN/A25.0044.1356.16Price / Book0.076.4710.097.06Net Income-$47M$158.81M$3.55B$335.04M7 Day PerformanceN/A3.55%4.71%2.60%1 Month PerformanceN/A-1.84%1.43%1.42%1 Year Performance-86.01%2.24%36.72%35.67% Venus Concept Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VEROVenus ConceptN/A$0.31flatN/AN/A$442K$58.88MN/A410GCTKGlucoTrack0.0801 of 5 stars$0.74-4.3%N/A-94.5%$1.50MN/AN/A5LYRALyra TherapeuticsN/A$0.73-1.2%N/A-85.1%$1.30M$600KN/A50Gap DownSSKNStrata Skin Sciences0.2023 of 5 stars$0.16+24.3%N/A-94.0%$758K$30.98MN/A120DYNTDynatronicsN/AN/AN/AN/A$653K$33.60MN/A200 Related Companies and Tools Related Companies GCTK Alternatives LYRA Alternatives SSKN Alternatives DYNT Alternatives XAGE Alternatives BIOL Alternatives WOK Alternatives SDCCQ Alternatives GMVDF Alternatives VRAYQ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERO) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Venus Concept Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Venus Concept With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
